Related Experiment Videos
Canadian regulatory requirements for recombinant fish vaccines
M S Sethi1, G A Gifford, B S Samagh
1Veterinary Biologic and Biotechnology Section, Animal and Plant Health Directorate, Agriculture and Agri-Food Canada, Nepean, Canada.
Developments in Biological Standardization
|January 1, 1997
Summary
Canada regulates veterinary biological products, including vaccines, based on purity, potency, safety, and efficacy. A risk-based approach guides the licensing of new biotechnology-derived products, such as recombinant fish vaccines.
Area of Science:
- Veterinary Medicine
- Biotechnology
- Regulatory Science
Background:
- Veterinary biological products are crucial for animal health, covering prevention, treatment, and diagnosis of infectious diseases across all animal species.
- Canada's regulatory framework, under the Health of Animals Act and Regulations, governs these products, including those developed using novel biotechnologies.
- Licensing requires meeting stringent criteria for purity, potency, safety, and efficacy.
Purpose of the Study:
- To outline the regulatory framework for licensing veterinary biological products in Canada.
- To emphasize regulatory considerations for novel products, specifically recombinant fish vaccines.
- To detail the pathway from research to commercialization for veterinary biologics.
Main Methods:
- Description of the Canadian regulatory system for veterinary biologicals.
- Application of a risk-based approach for safety evaluations (target/non-target species, humans, environment).
- Categorization of biotechnology-derived products into high and low-risk groups.
Main Results:
- Veterinary biologicals are licensed based on four key criteria: purity, potency, safety, and efficacy.
- A risk-based assessment is integral to evaluating product safety for diverse species and the environment.
- Biotechnology-derived products are classified by risk level, influencing regulatory pathways.
Conclusions:
- The Canadian regulatory system provides a structured approach for licensing veterinary biologicals, including innovative biotechnological products.
- Early consultation with regulatory bodies is recommended for manufacturers and researchers to ensure compliance and facilitate commercialization.
- The framework addresses the entire lifecycle of veterinary biologics, from contained research to market release, including field testing and environmental impact assessments.